ARK Invest renforce ses positions dans Meta et Rocket Lab tout en réduisant d’autres participations
Points clés
- •ARK a vendu 46,015 actions de Twist Bioscience d’une valeur d’environ $5.8 million via son ETF ARKK, prolongeant la réduction de cette position engagée depuis plusieurs semaines.
- •Deux fonds ARK ont acheté collectivement pour $27.9 million d’actions Meta Platforms le 9 septembre, renforçant leur exposition alors que le titre évoluait environ 18% sous son sommet historique.
- •Trois ETF ARK ont accumulé environ $45 million d’actions Rocket Lab entre le 31 août et le 8 septembre, dans un contexte marqué par une croissance du chiffre d’affaires de 62% sur un an et un carnet de commandes de $2.36 billion.
- •ARK a acheté près de 115,000 actions d’Intellia Therapeutics pour environ $1.4 million, poursuivant son accumulation de cette spécialiste de l’édition génétique.
- •L’ETF ARKK a enregistré un rendement d’environ 9% en 2026, inférieur à celui des principaux indices, tandis que quatre autres stratégies ARK ont surperformé le S\u0026P 500 sur les trois dernières années.
Cathie Wood’s ARK Invest made a series of portfolio adjustments on Friday, September 11, 2026, reducing several holdings while increasing its exposure to Meta Platforms, Rocket Lab and Intellia Therapeutics. The trades placed additional emphasis on artificial intelligence platforms, gene-editing technology and space-economy infrastructure, while also showing that the firm continued to reallocate capital within its existing portfolio rather than buying across all holdings.
The largest disclosed sale involved 46,015 shares of Twist Bioscience through the ARKK ETF, valued at approximately $5.8 million. The transaction continued a multi-week reduction in ARK’s position in the company.
ARK also sold 60,556 shares of 10X Genomics, worth nearly $4 million, and 121,217 shares of Bullish, valued at about $4.1 million. Smaller reductions affected positions in Tempus AI, GeneDx Holdings and Alphabet.
At the same time, ARK purchased nearly 115,000 shares of Intellia Therapeutics for approximately $1.4 million. The purchase extended the firm’s ongoing accumulation of the gene-editing specialist during the previous week.
ARK Funds Invest $27.9 Million in Meta
Two ARK funds collectively purchased $27.9 million in Meta Platforms (NASDAQ: META) shares on September 9. Meta’s stock was trading approximately 18% below its historical peak. The purchase therefore added to ARK’s exposure to a large technology platform while its shares remained below that earlier high.
ARK’s research analysts have pointed to Meta’s ecosystem of 3.6 billion daily active users across its applications as a significant competitive moat. The company uses artificial intelligence to improve advertising precision and content curation throughout its platform portfolio.
Meta reported 28% year-over-year revenue growth in the second quarter. CEO Mark Zuckerberg said Meta’s advertising business was growing faster than the advertising operations of any competitor that has disclosed results, measured in absolute dollar terms.
Meta’s capital expenditure forecast for 2026 is between $165 billion and $169 billion. The report said Wood appears to expect those infrastructure investments to support higher free cash flow generation in subsequent periods. Meta’s forward price-to-earnings ratio is 21. The scale of that spending makes Meta’s artificial-intelligence expansion a material part of the company’s financial outlook, alongside its advertising growth.
ARK Accumulates Approximately $45 Million in Rocket Lab
Three ARK ETFs purchased approximately $45 million worth of Rocket Lab shares between August 31 and September 8. The space company’s stock had fallen nearly 60% from its record high of $151, reached earlier in 2026.
Rocket Lab reported 62% year-over-year revenue growth in the second quarter and an unprecedented backlog of $2.36 billion. The company also secured $437 million in new contract bookings since the end of March. These figures provide the reported operating backdrop for ARK’s purchases as the company expands its position in the space sector.
CEO Peter Beck described demand for launch services as “extreme.” Company leadership said launch windows available beyond 2029 are “extremely limited,” a condition that could create pricing power as industry demand increases.
Rocket Lab is also in the process of acquiring Iridium, which operates a constellation of 66 satellites serving more than 2.5 million subscribers. The transactions indicate that Wood’s investment thesis for Rocket Lab extends beyond launch services to broader space infrastructure.
ARK’s primary ARKK ETF has returned approximately 9% in 2026, trailing broader market indexes. Four other ARK strategies, however, have outperformed the S\u0026P 500 over the trailing three-year period. The mixed performance across strategies provides context for the latest trades: the purchases increase exposure to themes ARK favors, but they do not represent uniform performance across its funds.
The latest transactions place greater emphasis on AI-enabled technology platforms and orbital infrastructure as the final quarter of 2026 approaches.
Source: Blockonomi
